Soligenix (SNGX) Notes Payables (2013 - 2021)
Soligenix's (SNGX) quarterly Notes Payables came in at $394617.0 in Q1 2021, up 21.43% on a QoQ basis from $324979.0 in Q4 2020.
Soligenix (SNGX) Notes Payables (2013 - 2021) Analysis & Trends
Soligenix (SNGX) has 6 years of Notes Payables data on file, last reported at $394617.0 in Q1 2021.
- Quarterly Notes Payables changed N/A year-over-year to $394617.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $394617.0 (changed N/A YoY) and the FY2020 annual result came in at $324979.0, changed N/A from the prior year.
- Notes Payables improved to $394617.0 in Q1 2021, from $324979.0 in the prior quarter.
- In the past five years, Notes Payables ranged from a high of $394617.0 in Q1 2021 to a low of $185702.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.39 Bn | 132.54 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.47 Bn | 78.47 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.25 Bn | 60.07 Bn | 1.37 Bn |
| 4 | Moderna | 61.79 Bn | 56.66 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.27 Bn | 37.17 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.17 Bn | 27.86 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.61 Bn | 10.22 Bn | 668.28 Mn |
| 8 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - |
| 10 | Soligenix | 6.26 Mn | 6.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 394,617.00 |
| Dec 31, 2020 | 324,979.00 |
| Sep 30, 2020 | 255,341.00 |
| Jun 30, 2020 | 185,702.00 |
| Sep 30, 2016 | 1.32 Mn |
| Jun 30, 2016 | 1.15 Mn |
| Mar 31, 2016 | 1.67 Mn |
| Dec 31, 2015 | 292,719.00 |
| Sep 30, 2015 | 286,399.00 |
| Jun 30, 2015 | 6.20 Mn |
| Mar 31, 2015 | 5.15 Mn |
| Dec 31, 2014 | 3.79 Mn |
| Sep 30, 2014 | 7.43 Mn |
| Jun 30, 2014 | 8.77 Mn |
| Mar 31, 2014 | 9.52 Mn |
| Dec 31, 2013 | 8.28 Mn |
| Sep 30, 2013 | 9.98 Mn |
| Jun 30, 2013 | 5.18 Mn |